U.S., Jan. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07361354) titled 'A Phase 1 Ethnobridging TriaL of AGA2118 in Healthy Japanese, Chinese, and Caucasian ParticipantS (ATLAS)' on Jan. 16.
Brief Summary: This study will evaluate the effects of a single dose of AGA2118 in Japanese, Chinese, and Caucasian participants
Study Start Date: Jan. 05
Study Type: INTERVENTIONAL
Condition:
Healthy Participants
Pharmacokinetic Study
Intervention:
DRUG: AGA2118
Participants will receive AGA2118 administered by subcutaneous injection
Recruitment Status: RECRUITING
Sponsor: Angitia Incorporated Limited
Published by HT Digital Content Services with permission from Health Daily Digest....